Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17:474–502.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708.

Article  PubMed  CAS  Google Scholar 

Yu X, Ruan Y, Huang X, et al. Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes. Biochem Biophys Res Commun. 2020;523:140–6.

Article  PubMed  CAS  Google Scholar 

Wu BB, Leung KT, Poon EN. Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23031912.

Article  PubMed  PubMed Central  Google Scholar 

Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67:8839–46.

Article  PubMed  CAS  Google Scholar 

Wallace KB, Sardao VA, Oliveira PJ. Mitochondrial determinants of doxorubicin-induced cardiomyopathy. Circ Res. 2020;126:926–41.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Carvalho RA, Sousa RP, Cadete VJ, et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology. 2010;270:92–8.

Article  PubMed  CAS  Google Scholar 

Wei X, Zhao Z, Zhong R, Tan X. A comprehensive review of herbacetin: from chemistry to pharmacological activities. J Ethnopharmacol. 2021;279:114356.

Article  PubMed  CAS  Google Scholar 

Li L, Sapkota M, Kim SW, Soh Y. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Eur J Pharmacol. 2016;777:17–25.

Article  PubMed  CAS  Google Scholar 

Oqal M, Qnais E, Alqudah A, Gammoh O. Analgesic effect of the flavonoid herbacetin in nociception animal models. Eur Rev Med Pharmacol Sci. 2023;27:11236–48.

PubMed  CAS  Google Scholar 

Chen X, Jiang YH, Fei X, et al. Herbacetin inhibits asthma development by blocking the SGK1/NF-kappaB signaling pathway. J Asthma Allergy. 2024;17:703–16.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cai P, Cai T, Li X, et al. Herbacetin treatment remitted LPS induced inhibition of osteoblast differentiation through blocking AKT/NF-kappaB signaling pathway. Am J Transl Res. 2019;11:865–74.

PubMed  PubMed Central  CAS  Google Scholar 

Kim DJ, Lee MH, Liu K, et al. Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC. Carcinogenesis. 2017;38:1136–46.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang S, Wang Y, Yu M, et al. Discovery of Herbacetin as a Novel SGK1 Inhibitor to Alleviate Myocardial Hypertrophy. Adv Sci (Weinh). 2022;9:e2101485.

Article  PubMed  Google Scholar 

Vandergriff AC, Hensley MT, Cheng K. Isolation and cryopreservation of neonatal rat cardiomyocytes. J Vis Exp. 2015;98:52726.

Google Scholar 

Chen S, Chen J, Du W, et al. PDE10A inactivation prevents doxorubicin-induced cardiotoxicity and tumor growth. Circ Res. 2023;133:138–57.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kumari M, Sharma A, Tirpude NV. Herbacetin ameliorates lipopolysaccharide-elicited inflammatory response by suppressing NLRP-3/AIM-2 inflammasome activation, PI3K/Akt/MAPKs/NF-kappaB redox inflammatory signalling, modulating autophagy and macrophage polarization imbalance. Mol Biol Rep. 2024;51:1159.

Article  PubMed  CAS  Google Scholar 

Kim DJ, Roh E, Lee MH, et al. Herbacetin is a novel allosteric inhibitor of ornithine decarboxylase with antitumor activity. Cancer Res. 2016;76:1146–57.

Article  PubMed  CAS  Google Scholar 

Ijaz MU, Mustafa S, Batool R, Naz H, Ahmed H, Anwar H. Ameliorative effect of herbacetin against cyclophosphamide-induced nephrotoxicity in rats via attenuation of oxidative stress, inflammation, apoptosis and mitochondrial dysfunction. Hum Exp Toxicol. 2022;41:9603271221132140.

Article  PubMed  CAS  Google Scholar 

Martin-Vega A, Cobb MH. Navigating the ERK1/2 MAPK cascade. Biomolecules. 2023. https://doi.org/10.3390/biom13101555.

Article  PubMed  PubMed Central  Google Scholar 

Wu J, Feng A, Liu C, et al. Genistein alleviates doxorubicin-induced cardiomyocyte autophagy and apoptosis via ERK/STAT3/c-Myc signaling pathway in rat model. Phytother Res. 2024;38:3921–34.

Article  PubMed  CAS  Google Scholar 

Cui S, Zhang X, Li Y, et al. UGCG modulates heart hypertrophy through B4GalT5-mediated mitochondrial oxidative stress and the ERK signaling pathway. Cell Mol Biol Lett. 2023;28:71.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang JY, Zong CS, Xia W, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hu J, Liu T, Fu F, et al. Omentin1 ameliorates myocardial ischemia-induced heart failure via SIRT3/FOXO3a-dependent mitochondrial dynamical homeostasis and mitophagy. J Transl Med. 2022;20:447.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu K, Zhu Y, Gao W, et al. Resveratrol alleviates heart failure by activating foxo3a to counteract oxidative stress and apoptosis. Biomed Pharmacother. 2024;181:117716.

Article  PubMed  CAS  Google Scholar 

Chen DS, Yan J, Yang PZ. Cardiomyocyte atrophy, an underestimated contributor in doxorubicin-induced cardiotoxicity. Front Cardiovasc Med. 2022;9:812578.

Article  PubMed  PubMed Central  CAS  Google Scholar